Let’s look at the key reasons that are pushing CytomX Therapeutics Inc (CTMX) to new highs

On Monday, CytomX Therapeutics Inc (NASDAQ: CTMX) opened lower -3.82% from the last session, before settling in for the closing price of $1.31. Price fluctuations for CTMX have ranged from $1.04 to $5.85 over the past 52 weeks.

Healthcare Sector giant saw their annual sales surged by 28.25% over the last five years. Company’s average yearly earnings per share was noted -1825.60% at the time writing. With a float of $73.11 million, this company’s outstanding shares have now reached $77.92 million.

The firm has a total of 122 workers. Let’s measure their productivity.

CytomX Therapeutics Inc (CTMX) Breakdown of a Key Holders of the stock

A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of CytomX Therapeutics Inc is 6.17%, while institutional ownership is 67.14%. The most recent insider transaction that took place on Mar 19 ’24, was worth 42,175. In this transaction CEO of this company sold 20,223 shares at a rate of $2.09, taking the stock ownership to the 524,481 shares. Before that another transaction happened on Mar 19 ’24, when Company’s SVP, Chief Scientific Officer sold 12,795 for $2.09, making the entire transaction worth $26,684. This insider now owns 168,579 shares in total.

CytomX Therapeutics Inc (CTMX) Recent Fiscal highlights

According to the Wall Street analysts, stocks earnings will be around -1825.60% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -0.90% during the next five years compared to 67.21% growth over the previous five years of trading.

CytomX Therapeutics Inc (NASDAQ: CTMX) Trading Performance Indicators

Check out the current performance indicators for CytomX Therapeutics Inc (CTMX). In the past quarter, the stock posted a quick ratio of 1.16. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.82.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.20, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.55 in one year’s time.

Technical Analysis of CytomX Therapeutics Inc (CTMX)

Analysing the last 5-days average volume posted by the [CytomX Therapeutics Inc, CTMX], we can find that recorded value of 0.63 million was lower than the volume posted last year of 3.39 million. As of the previous 9 days, the stock’s Stochastic %D was 21.33%. Additionally, its Average True Range was 0.09.

During the past 100 days, CytomX Therapeutics Inc’s (CTMX) raw stochastic average was set at 2.75%, which indicates a significant decrease from 19.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 54.04% in the past 14 days, which was lower than the 222.88% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $1.4462, while its 200-day Moving Average is $1.7014. Now, the first resistance to watch is $1.2867. This is followed by the second major resistance level at $1.3133. The third major resistance level sits at $1.3567. If the price goes on to break the first support level at $1.2167, it is likely to go to the next support level at $1.1733. Now, if the price goes above the second support level, the third support stands at $1.1467.

CytomX Therapeutics Inc (NASDAQ: CTMX) Key Stats

There are currently 77,919K shares outstanding in the company with a market cap of 98.18 million. Presently, the company’s annual sales total 101,210 K according to its annual income of -570 K. Last quarter, the company’s sales amounted to 41,460 K and its income totaled 13,790 K.